Nabriva Therapeutics PLC NBRVF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–2.24
- Bid/Ask
- $0.25 / $0.51
- Market Cap
- $323.08
- Volume/Avg
- 1,354 / 1,559
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 39
- Website
- https://www.nabriva.com
Valuation
|
Metric
|
NBRVF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NBRVF
|
|---|---|
Quick Ratio | 0.25 |
Current Ratio | 0.38 |
Interest Coverage | −112.20 |
Quick Ratio
NBRVF
Profitability
|
Metric
|
NBRVF
|
|---|---|
Return on Assets (Normalized) | −157.64% |
Return on Equity (Normalized) | −624.84% |
Return on Invested Capital (Normalized) | −425.55% |
Return on Assets
NBRVF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nszqwdbs | Mszf | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bqwdrlqv | Tybjs | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ysrcmlv | Hppldl | $97.8 Bil | |
MRNA
| Moderna Inc | Mbzgkbjr | Xlvz | $41.3 Bil | |
ARGX
| argenx SE ADR | Kwzqrzsd | Nsyk | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Pzzgfwpz | Vws | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ydpfkvbkf | Rwydwj | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Btjpyvgbt | Cbcqm | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ltpbcbsbfw | Fysqg | $12.5 Bil | |
INCY
| Incyte Corp | Nzlpsddj | Rtnmwpy | $11.6 Bil |